KC7F2
中文名稱(chēng) | KC7F2 |
---|---|
中文同義詞 | 化合物ML228;ML 228,HIF通路激活劑 |
英文名稱(chēng) | ML-228 |
英文同義詞 | ML-228;N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine;ML228; ML 228;N-([1,1'Biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine;CID-46742353;ML-228;CID-46742353;L-228;1,2,4-Triazin-5-amine, N-([1,1'-biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)- |
CAS號(hào) | 1357171-62-0 |
分子式 | C27H21N5 |
分子量 | 415.49 |
EINECS號(hào) | |
相關(guān)類(lèi)別 | |
Mol文件 | 1357171-62-0.mol |
結(jié)構(gòu)式 |
KC7F2 性質(zhì)
沸點(diǎn) | 686.0±65.0 °C(Predicted) |
---|---|
密度 | 1.228±0.06 g/cm3(Predicted) |
儲(chǔ)存條件 | -20°C, Inert atmosphere |
溶解度 | 可溶于DMSO(少許)、甲醇(少許) |
形態(tài) | 固體 |
酸度系數(shù)(pKa) | 2.03±0.63(Predicted) |
顏色 | 淡黃色至淺黃色 |
EC50: 1 μM (HIF)
ML228 (CID-46742353) represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications.
ML228 (injection; 1 μg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function.
Animal Model: | SD rat |
Dosage: | 1 μg/kg |
Administration: | injection; 7 days |
Result: | Alleviated SCI of the central nervous system and relieve associated symptoms. |
安全信息
更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
---|---|---|---|---|---|
2024/11/08 | HY-12754 | ML228 | 1 mg | 450元 | |
2024/11/08 | HY-12754 | KC7F2 ML228 | 1357171-62-0 | 5mg | 990元 |